Abbott, Liquidia to develop siRNA therapeutics
This article was originally published in Clinica
Liquidia Technologies is set to develop its Print nanoparticle technology for the delivery of siRNA-based therapeutics alongside Abbott Laboratories, after the two firms signed a collaboration and licence agreement. The partnership will see Liquidia (Research Triangle Park, North Carolina) provide Abbott with certain rights to its Print technology, in order to develop and commercialise more targeted, safer and effective siRNA therapeutics for cancer patients. According to Liquidia, the Print technology can achieve this by making nanoparticles with customised size, shape, surface chemistry and composition. Financial terms of the deal were not revealed.